Johnson and Johnson
Innovative Tech Critical in Vaccinating South Africa’s Rural and Remote Areas
/* custom css */ .tdi_4_9b2.td-a-rec-img{ text-align: left; }.tdi_4_9b2.td-a-rec-img img{ margin: 0 auto 0 0; } As South Africa’s COVID-19 vaccination programme ramps up, with a target to vaccinate 41-million people by the end of March next year, health NGO Right to Care is deploying teams to vaccinate South Africans living in hard-to-reach places in remote parts of the country. Dr Ntombi Sigwebela, chief of party for vaccinations at health NGO Right to Care, says that “No-one should be left out of the vaccine programme, including people living in far-flung areas. There is an urgency to vaccinate as variants may emerge and spread. We need to achieve herd or population immunity to break the chain of transmission as quickly as possible.” Right to Care is supporting the National Department of...
Britain secures early access to promising vaccine candidates
The British government on Friday announced that it had secured early access to 90 million doses of two new promising vaccine candidates. British citizens will receive early access to 90 million doses of the two COVID-19 vaccine candidates should they prove safe and effective. By far, the British government has secured access to six different vaccine candidates as part of the government’s strategy to build a portfolio of promising new vaccines should any be found to be safe and effective. The government has also agreed in principle to co-fund a global clinical trial with the Janssen Pharmaceutical Companies of Johnson and Johnson to establish how effective their vaccine could be in providing long-term immunity against COVID-19. The next phase of Janssen’s clinical trials is expected to begi...
